Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller, Vera Hirsh, Jacques L. Cadranel et al. · The Lancet Oncology · 2012
Cited by 956 works. doi:10.1016/s1470-2045(12)70087-6
Authors
- Vincent A. Miller
- Vera Hirsh
- Jacques L. Cadranel
- Yuh-Min Chen
- Keunchil Park
- Sang-We Kim
- Caicun Zhou
- Wu‐Chou Su
- Mengzhao Wang
- Yan Kui Sun
- Dae Seog Heo
- Lucio Crinò
- Eng-Huat Tan
- Tsu-Yi Chao
- Mehdi Shahidi
- Xiuyu Julie Cong
- Robert M. Lorence
- James Chih‐Hsin Yang
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- EORTC QLQ-C30 Scoring Manual
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
- Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions